The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
NLRP3 and pyroptosis blockers for treating inflammatory diseases
Open accessAbstract
The nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing protein 3 (NLRP3) inflammasome has emerged as a key mediator of pathological inflammation in many diseases and is an exciting drug target. Here, we review the molecular basis of NLRP3 inhibition by drug-like small molecules under development as novel therapeutics. We also summarize recent strategies to block pyroptosis as a novel approach to suppress chronic inflammation. Major recent developments in this area include the elucidation of mechanisms of action (MoAs) by which small molecules block NLRP3 inflammasome assembly and gasdermin D (GSDMD)-induced pyroptosis. We also discuss the status of clinical trials using agents that block specific components of the NLRP3 pathway, including their potential clinical applications for the treatment of many diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
Bauernfeind, F. G., Horvath, G., Stutz, A., Alnemri, E. S., MacDonald, K., Speert, D., Fernandes-Alnemri, T., Wu, J., Monks, B. G., Fitzgerald, K. A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901363 · Cited by 2,959
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
Self-citationMixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase
Sun, L., Wang, H., Wang, Z., He, S., Chen, S., Liao, D., Wang, L., Yan, J., Liu, W., Lei, X., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.031 · Cited by 2,698
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
The gasdermins, a protein family executing cell death and inflammation
Broz, P., Pelegrín, P., & Shao, F. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0228-2 · Cited by 1,641
Self-citationNLRP3 inflammasome activation drives tau pathology
Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., et al. (2019) · Nature · doi:10.1038/s41586-019-1769-z · Cited by 1,487
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437
Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells
Zhou, Z., He, H., Wang, K., Shi, X., Wang, Y., Su, Y., Wang, Y., Li, D., Liu, W., Zhang, Y., et al. (2020) · Science · doi:10.1126/science.aaz7548 · Cited by 1,317
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
Hu, J. J., Liu, X., Xia, S., Zhang, Z., Zhang, Y., Zhao, J., Ruan, J., Luo, X., Lou, X., Bai, Y., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0669-6 · Cited by 1,145
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110
Self-citationMCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
Coll, R. C., Hill, J. R., Day, C. J., Zamoshnikova, A., Boucher, D., Massey, N. L., Chitty, J. L., Fraser, J. A., Jennings, M. P., Robertson, A. A. B., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0277-7 · Cited by 1,014
Self-citationColitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome
Bauer, C., Duewell, P., Mayer, C., Lehr, H. A., Fitzgerald, K. A., Dauer, M., Tschopp, J., Endres, S., Latz, E., & Schnurr, M. (2010) · Gut · doi:10.1136/gut.2009.197822 · Cited by 906
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice
Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897
Self-citationEichele, D. D., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i33.6016 · Cited by 879
NINJ1 mediates plasma membrane rupture during lytic cell death
Kayagaki, N., Kornfeld, O. S., Lee, B. L., Stowe, I. B., O’Rourke, K., Li, Q., Sandoval, W., Yan, D., Kang, J., Xu, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03218-7 · Cited by 857
Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity
He, H., Jiang, H., Chen, Y., Ye, J., Wang, A., Wang, C., Liu, Q., Liang, G., Deng, X., Jiang, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04947-6 · Cited by 827
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome
Lamkanfi, M., Mueller, J. L., Vitari, A. C., Misaghi, S., Fedorova, A., Deshayes, K., Lee, W. P., Hoffman, H. M., & Dixit, V. M. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200903124 · Cited by 820
Baroja-Mazo, A., Martín-Sánchez, F., Gomez, A. I., Martínez, C. M., Amores-Iniesta, J., Compan, V., Barberà-Cremades, M., Yagüe, J., Ruiz-Ortiz, E., Antón, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2919 · Cited by 790
Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders
Jiang, H., He, H., Chen, Y., Huang, W., Cheng, J., Ye, J., Wang, A., Tao, J., Wang, C., Liu, Q., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171419 · Cited by 748
Succination inactivates gasdermin D and blocks pyroptosis
Humphries, F., Shmuel-Galia, L., Ketelut-Carneiro, N., Li, S., Wang, B., Nemmara, V. V., Wilson, R., Jiang, Z., Khalighinejad, F., Muneeruddin, K., et al. (2020) · Science · doi:10.1126/science.abb9818 · Cited by 670
Gasdermin D pore structure reveals preferential release of mature interleukin-1
Xia, S., Zhang, Z., Magupalli, V. G., Pablo, J. L., Dong, Y., Vora, S. M., Wang, L., Fu, T.-M., Jacobson, M. P., Greka, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03478-3 · Cited by 642
Rathkey, J. K., Zhao, J., Liu, Z., Chen, Y., Yang, J., Kondolf, H. C., Benson, B. L., Chirieleison, S. M., Huang, A. Y., Dubyak, G. R., et al. (2018) · Science Immunology · doi:10.1126/sciimmunol.aat2738 · Cited by 612
Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the Inflammasome
Juliana, C., Fernandes-Alnemri, T., Wu, J., Datta, P., Solorzano, L., Yu, J.-W., Meng, R., Quong, A. A., Latz, E., Scott, C. P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.082305 · Cited by 610
Marchetti, C., Swartzwelter, B., Gamboni, F., Neff, C. P., Richter, K., Azam, T., Carta, S., Tengesdal, I., Nemkov, T., D’Alessandro, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716095115 · Cited by 574
Dempsey, C., Rubio Araiz, A., Bryson, K. J., Finucane, O., Larkin, C., Mills, E. L., Robertson, A. A. B., Cooper, M. A., O'Neill, L. A. J., & Lynch, M. A. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.12.014 · Cited by 571
Tranilast directly targets NLRP 3 to treat inflammasome‐driven diseases
Huang, Y., Jiang, H., Chen, Y., Wang, X., Yang, Y., Tao, J., Deng, X., Liang, G., Zhang, H., Jiang, W., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708689 · Cited by 507
Stancu, I.-C., Cremers, N., Vanrusselt, H., Couturier, J., Vanoosthuyse, A., Kessels, S., Lodder, C., Brône, B., Huaux, F., Octave, J.-N., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-01957-y · Cited by 447
MCC950 closes the active conformation of NLRP3 to an inactive state
Tapia-Abellán, A., Angosto-Bazarra, D., Martínez-Banaclocha, H., de Torre-Minguela, C., Cerón-Carrasco, J. P., Pérez-Sánchez, H., Arostegui, J. I., & Pelegrin, P. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0278-6 · Cited by 439
Control of gasdermin D oligomerization and pyroptosis by the Ragulator-Rag-mTORC1 pathway
Evavold, C. L., Hafner-Bratkovič, I., Devant, P., D’Andrea, J. M., Ngwa, E. M., Boršić, E., Doench, J. G., LaFleur, M. W., Sharpe, A. H., Thiagarajah, J. R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.028 · Cited by 417
Franke, M., Bieber, M., Kraft, P., Weber, A. N. R., Stoll, G., & Schuhmann, M. K. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.12.009 · Cited by 382
Inflammasome signaling and regulation of interleukin-1 family cytokines
Chan, A. H., & Schroder, K. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190314 · Cited by 373
Self-citationMyeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome
Neudecker, V., Haneklaus, M., Jensen, O., Khailova, L., Masterson, J. C., Tye, H., Biette, K., Jedlicka, P., Brodsky, K. S., Gerich, M. E., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160462 · Cited by 356
Inflammasome activation at the crux of severe COVID-19
Vora, S. M., Lieberman, J., & Wu, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00588-x · Cited by 325
Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3
Hochheiser, I. V., Pilsl, M., Hagelueken, G., Moecking, J., Marleaux, M., Brinkschulte, R., Latz, E., Engel, C., & Geyer, M. (2022) · Nature · doi:10.1038/s41586-022-04467-w · Cited by 312
Klück, V., Jansen, T. L. T. A., Janssen, M., Comarniceanu, A., Efdé, M., Tengesdal, I. W., Schraa, K., Cleophas, M. C. P., Scribner, C. L., Skouras, D. B., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30065-5 · Cited by 311
Monteleone, M., Stanley, A. C., Chen, K. W., Brown, D. L., Bezbradica, J. S., von Pein, J. B., Holley, C. L., Boucher, D., Shakespear, M. R., Kapetanovic, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.027 · Cited by 306
Self-citationLonnemann, N., Hosseini, S., Marchetti, C., Skouras, D. B., Stefanoni, D., D’Alessandro, A., Dinarello, C. A., & Korte, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009680117 · Cited by 298
Perera, A. P., Fernando, R., Shinde, T., Gundamaraju, R., Southam, B., Sohal, S. S., Robertson, A. A. B., Schroder, K., Kunde, D., & Eri, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-26775-w · Cited by 295
Self-citationNLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation
Andreeva, L., David, L., Rawson, S., Shen, C., Pasricha, T., Pelegrin, P., & Wu, H. (2021) · Cell · doi:10.1016/j.cell.2021.11.011 · Cited by 292
Tan, G., Huang, C., Chen, J., & Zhi, F. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00985-0 · Cited by 290
Toward targeting inflammasomes: insights into their regulation and activation
Christgen, S., Place, D. E., & Kanneganti, T.-D. (2020) · Cell Research · doi:10.1038/s41422-020-0295-8 · Cited by 281
Inflammasome-dependent IL-1β release depends upon membrane permeabilisation
Martín-Sánchez, F., Diamond, C., Zeitler, M., Gomez, A. I., Baroja-Mazo, A., Bagnall, J., Spiller, D., White, M., Daniels, M. J. D., Mortellaro, A., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.176 · Cited by 279
Self-citationWard, R., Li, W., Abdul, Y., Jackson, L., Dong, G., Jamil, S., Filosa, J., Fagan, S. C., & Ergul, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.035 · Cited by 270
He, Y., Varadarajan, S., Muñoz-Planillo, R., Burberry, A., Nakamura, Y., & Núñez, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.515080 · Cited by 268
Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke
Ismael, S., Zhao, L., Nasoohi, S., & Ishrat, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-24350-x · Cited by 236
Demarco, B., Grayczyk, J. P., Bjanes, E., Le Roy, D., Tonnus, W., Assenmacher, C.-A., Radaelli, E., Fettrelet, T., Mack, V., Linkermann, A., et al. (2020) · Science Advances · doi:10.1126/sciadv.abc3465 · Cited by 236
Martínez-García, J. J., Martínez-Banaclocha, H., Angosto-Bazarra, D., de Torre-Minguela, C., Baroja-Mazo, A., Alarcón-Vila, C., Martínez-Alarcón, L., Amores-Iniesta, J., Martín-Sánchez, F., Ercole, G. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10626-x · Cited by 233
Cheng, J., Liao, Y., Dong, Y., Hu, H., Yang, N., Kong, X., Li, S., Li, X., Guo, J., Qin, L., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1719723 · Cited by 233
Ren, H., Kong, Y., Liu, Z., Zang, D., Yang, X., Wood, K., Li, M., & Liu, Q. (2018) · Stroke · doi:10.1161/strokeaha.117.018904 · Cited by 226
Perregaux, D. G., McNiff, P., Laliberte, R., Hawryluk, N., Peurano, H., Stam, E., Eggler, J., Griffiths, R., Dombroski, M. A., & Gabel, C. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29317-4 · Cited by 216
Laliberte, R. E., Perregaux, D. G., Hoth, L. R., Rosner, P. J., Jordan, C. K., Peese, K. M., Eggler, J. F., Dombroski, M. A., Geoghegan, K. F., & Gabel, C. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211596200 · Cited by 206
Wu, M., Yang, Z., Zhang, C., Shi, Y., Han, W., Song, S., Mu, L., Du, C., & Shi, Y. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154748 · Cited by 192
Hou, B., Zhang, Y., Liang, P., He, Y., Peng, B., Liu, W., Han, S., Yin, J., & He, X. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2565-2 · Cited by 187
Wohlford, G. F., Van Tassell, B. W., Billingsley, H. E., Kadariya, D., Canada, J. M., Carbone, S., Mihalick, V. L., Bonaventura, A., Vecchié, A., Chiabrando, J. G., et al. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000931 · Cited by 178
Corcoran, S. E., Halai, R., & Cooper, M. A. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000171 · Cited by 173
Ismael, S., Nasoohi, S., & Ishrat, T. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2017.5344 · Cited by 171
Dekker, C., Mattes, H., Wright, M., Boettcher, A., Hinniger, A., Hughes, N., Kapps-Fouthier, S., Eder, J., Erbel, P., Stiefl, N., et al. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167309 · Cited by 167
Vande Walle, L., Stowe, I. B., Šácha, P., Lee, B. L., Demon, D., Fossoul, A., Van Hauwermeiren, F., Saavedra, P. H. V., Šimon, P., Šubrt, V., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000354 · Cited by 166
Cocco, M., Pellegrini, C., Martínez-Banaclocha, H., Giorgis, M., Marini, E., Costale, A., Miglio, G., Fornai, M., Antonioli, L., López-Castejón, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01624 · Cited by 165
Self-citationSun, R., Peng, M., Xu, P., Huang, F., Xie, Y., Li, J., Hong, Y., Guo, H., Liu, Q., & Zhu, W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01988-x · Cited by 165
Sánchez-Fernández, A., Skouras, D. B., Dinarello, C. A., & López-Vales, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02578 · Cited by 164
Tapia‐Abellán, A., Angosto-Bazarra, D., Alarcón‐Vila, C., Baños, M. C., Hafner‐Bratkovič, I., Oliva, B., & Pelegrín, P. (2021) · Science Advances · doi:10.1126/sciadv.abf4468 · Cited by 157
Self-citationSpecific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis
Admin, A., Sharma, A., Choi, J. S. Y., Stefanovic, N., Sharea, A.-A., Simpson, D. S., Nigora, M., Jandeleit, K., Murphy, A. J., Sviridov, D., et al. (2020) · Diabetes · doi:10.2337/db20-0357 · Cited by 148
Bellut, M., Papp, L., Bieber, M., Kraft, P., Stoll, G., & Schuhmann, M. K. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04379-z · Cited by 146
Gasdermins mediate cellular release of mitochondrial DNA during pyroptosis and apoptosis
de Torre‐Minguela, C., Gómez, A. I., Couillin, I., & Pelegrín, P. (2021) · The FASEB Journal · doi:10.1096/fj.202100085r · Cited by 145
Self-citationMalhotra, S., Costa, C., Eixarch, H., Keller, C. W., Amann, L., Martínez‐Banaclocha, H., Midaglia, L. S., Sarró, E., Machín-Díaz, I., Villar, L. M., et al. (2020) · Brain · doi:10.1093/brain/awaa084 · Cited by 144
Self-citationRRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor
Chen, Y., He, H., Lin, B., Chen, Y., Deng, X., Jiang, W., & Zhou, R. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00683-y · Cited by 143
Zhai, Y., Meng, X., Ye, T., Xie, W., Sun, G., & Sun, X. (2018) · Molecules · doi:10.3390/molecules23030522 · Cited by 130
Zhang, C., Zhu, X., Li, L., Ma, T., Shi, M., Yang, Y., & Fan, Q. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s199802 · Cited by 126
Glyburide Is Anti-inflammatory and Associated with Reduced Mortality in Melioidosis
Koh, G. C. K. W., Maude, R. R., Schreiber, M. F., Limmathurotsakul, D., Wiersinga, W. J., Wuthiekanun, V., Lee, S. J., Mahavanakul, W., Chaowagul, W., Chierakul, W., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq192 · Cited by 118
Guo, C., Fulp, J., Jiang, Y., Li, X., Chojnacki, J. E., Wu, J., Wang, X., & Zhang, S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00124 · Cited by 113
Qu, J., Yuan, Z., Wang, G., Wang, X., & Li, K. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.02.016 · Cited by 96
Shim, D.-W., Shin, W.-Y., Yu, S., Kim, B.-H., Ye, S.-K., Koppula, S., Won, H., Kang, T., & Lee, K.-H. (2017) · Scientific Reports · doi:10.1038/s41598-017-15314-8 · Cited by 91
Zhang, W., Fang, Z., & Liu, W. (2019) · Parasites & Vectors · doi:10.1186/s13071-018-3223-8 · Cited by 86
Wu, D., Wu, K., Zhu, Q., Xiao, W., Shan, Q., Yan, Z., Wu, J., Deng, B., Xue, Y., Gong, W., et al. (2018) · Mediators of Inflammation · doi:10.1155/2018/3048532 · Cited by 83
A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target
Kennedy, C. R., Goya Grocin, A., Kovačič, T., Singh, R., Ward, J. A., Shenoy, A. R., & Tate, E. W. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00218 · Cited by 81
Huang, S., Chen, Z., Fan, B., Chen, Y., Zhou, L., Jiang, B., Long, H., Zhong, W., Li, X., & Li, Y. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577543 · Cited by 80
ATP-Binding and Hydrolysis in Inflammasome Activation
Sandall, C. F., Ziehr, B. K., & MacDonald, J. A. (2020) · Molecules · doi:10.3390/molecules25194572 · Cited by 78
Saber, S., Youssef, M. E., Sharaf, H., Amin, N. A., El-Shedody, R., Aboutouk, F. H., El-Galeel, Y. A., El-Hefnawy, A., Shabaka, D., Khalifa, A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119123 · Cited by 78
Saber, S., & El-Kader, E. M. A. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00730-6 · Cited by 76
Inhibition of NLRP3 Inflammasome Ameliorates Cerebral Ischemia-Reperfusion Injury in Diabetic Mice
Hong, P., Li, F., Gu, R., Fang, Y., Lai, L., Wang, Y., Tao, T., Xu, S., You, Z.-J., & Zhang, H. (2018) · Neural Plasticity · doi:10.1155/2018/9163521 · Cited by 74
Targeting Inflammasomes to Treat Neurological Diseases
Lünemann, J. D., Malhotra, S., Shinohara, M. L., Montalbán, X., & Comabella, M. (2021) · Annals of Neurology · doi:10.1002/ana.26158 · Cited by 73
Wang, Q., Wei, S., Zhou, S., Qiu, J., Shi, C., Liu, R., Zhou, H., & Lü, L. (2019) · Immunology and Cell Biology · doi:10.1111/imcb.12297 · Cited by 72
Identification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
Soriano‐Teruel, P. M., García‐Laínez, G., Marco-Salvador, M., Pardo, J., Arias, M. A., DeFord, C., Merfort, I., Vicent, M. J., Pelegrín, P., Sancho, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04420-1 · Cited by 72
Self-citationProtection of MCC950 against Alzheimer's disease via inhibiting neuronal pyroptosis in SAMP8 mice
Li, J., Zhuang, L., Luo, X., Liang, J., Sun, E., & He, Y. (2020) · Experimental Brain Research · doi:10.1007/s00221-020-05916-6 · Cited by 69
Budden, C. F., Gearing, L. J., Kaiser, R., Standke, L., Hertzog, P. J., & Latz, E. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12127 · Cited by 68
Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis†
Uno, M., Kurita, S., Misu, H., Ando, H., Ota, T., Nagata, N., Kita, Y., Nabemoto, S., Akahori, H., Zen, Y., et al. (2008) · Hepatology · doi:10.1002/hep.22338 · Cited by 67
Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors
Hill, J. R., Coll, R. C., Sue, N., Reid, J. C., Dou, J., Holley, C. L., Pelingon, R., Dickinson, J. B., Biden, T. J., Schroder, K., et al. (2017) · ChemMedChem · doi:10.1002/cmdc.201700270 · Cited by 67
Self-citationHe, X., Xu, J., Li, G., Li, M., Li, L., Pei, Z., Zhang, L., & Hu, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03072-x · Cited by 67
NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages
Shi, Y., Lv, Q., Zheng, M., Sun, H., & Shi, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107358 · Cited by 67
Pu, Z., Han, C., Zhang, W., Xu, M., Wu, Z., Liu, Y., Wu, M., Sun, H., & Xie, H. (2019) · PubMed · Cited by 66
Marín‐Aguilar, F., Castejón‐Vega, B., Alcocer‐Gómez, E., Lendines‐Cordero, D., Cooper, M. A., de la Cruz‐Ojeda, P., Andújar, E., Pérez-Alegre, M., Muntané, J., Pérez‐Pulido, A. J., et al. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz239 · Cited by 65
Zhang, J., Xia, L., Zhang, F., Zhu, D., Xin, C., Wang, H., Zhang, F., Guo, X., Lee, Y., Zhang, L., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.02.012 · Cited by 64
NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice
Wang, X., Sun, K., Zhou, Y., Wang, H., Zhou, Y., Liu, S., Nie, Y., & Li, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.009 · Cited by 64
Østergaard, J. A., Jha, J. C., Sharma, A., Dai, A., Choi, J. S. Y., de Haan, J. B., Cooper, M. E., & Jandeleit-Dahm, K. (2022) · Clinical Science · doi:10.1042/cs20210865 · Cited by 61
Wang, H., Zhong, D., Chen, H., Jin, J., Liu, Q., & Li, G. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.031 · Cited by 58
Agarwal, S., Sasane, S., Shah, H. A., Pethani, J. P., Deshmukh, P. H., Vyas, V., Iyer, P. S., Bhavsar, H., Viswanathan, K., Bandyopadhyay, D., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00433 · Cited by 57
Pellegrini, C., Fornai, M., Colucci, R., Benvenuti, L., D’Antongiovanni, V., Natale, G., Fulceri, F., Giorgis, M., Marini, E., Gastaldi, S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01405 · Cited by 53
Wang, S., Zhang, Y., Saas, P., et al. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12710 · Cited by 50
Saber, S., El-Kader, E. M. A., Sharaf, H., El-Shamy, R., El-Saeed, B., Mostafa, A., Ezzat, D., & Shata, A. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115075 · Cited by 50
Lemarchand, E., Barrington, J., Chenery, A., Haley, M., Coutts, G., Allen, J. E., Allan, S. M., & Brough, D. (2019) · Stroke · doi:10.1161/strokeaha.118.023620 · Cited by 49
Time‐dependent dual effect of NLRP3 inflammasome in brain ischaemia
Palomino‐Antolín, A., Narros‐Fernández, P., Farré‐Alins, V., Sevilla‐Montero, J., Decouty‐Pérez, C., López-Rodríguez, A. B., Fernández, N., Monge, L., Casas, A. I., Calzada, M. J., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15732 · Cited by 48
Evidence against a role for NLRP3-driven islet inflammation in db/db mice
Kammoun, H. L., Allen, T. L., Henstridge, D. C., Barre, S., Coll, R. C., Lancaster, G. I., Cron, L., Reibe, S., Chan, J. Y., Bensellam, M., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.02.001 · Cited by 46
Self-citationLiu, D., Qin, H., Bi-xian, Y., Du, B., & Xue-lin, Y. (2020) · Drug Development Research · doi:10.1002/ddr.21649 · Cited by 42
Fekete, C., Vastagh, C., Dénes, Á., Hrabovszky, E., Nyíri, G., Kalló, I., Liposits, Z., & Sárvári, M. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.046 · Cited by 41
The NLRP3 inflammasome mediates DSS-induced intestinal inflammation in Nod2 knockout mice
Umiker, B., Lee, H., Cope, J. L., Ajami, N. J., Lainé, J., Fregeau, C., Ferguson, H. M., Alves, S. E., Sciammetta, N., Kleinschek, M. A., et al. (2019) · Innate Immunity · doi:10.1177/1753425919826367 · Cited by 32
Zou, W., 张正威, Luo, S., Cheng, L., Huang, X., Ding, N., Yu, J., Pan, Y., & Wu, Z. (2020) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2020.4833 · Cited by 31
Oizumi, T., Mayanagi, T., Toya, Y., Sugai, T., Matsumoto, T., & Sobue, K. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07184-y · Cited by 31
Lowe, P., Cho, Y., Tornai, D., Çoban, Ş., Catalano, D., & Szabó, G. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14272 · Cited by 27
Identification of a novel orally bioavailable NLRP3 inflammasome inhibitor
Agarwal, S., Pethani, J. P., Shah, H. A., Vyas, V., Sasane, S., Bhavsar, H., Bandyopadhyay, D., Giri, P., Viswanathan, K., Jain, M. R., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127571 · Cited by 26
Torres, S., Brol, M. J., Magdaleno, F., Schierwagen, R., Uschner, F. E., Klein, S., Ortiz, C., Tyc, O., Bachtler, N., Stunden, J., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.715765 · Cited by 26
Sun, K., Wang, J., Lan, Z., Li, L., Wang, Y., Li, A., Liu, S., & Li, Y. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04571-8 · Cited by 24
Application of immobilized ATP to the study of NLRP inflammasomes
Liao, K., Sandall, C. F., Carlson, D. A., Ulke‐Lemée, A., Platnich, J. M., Hughes, P. F., Muruve, D. A., Haystead, T., & MacDonald, J. A. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2018.12.031 · Cited by 22
Gastaldi, S., Boscaro, V., Gianquinto, E., Sandall, C. F., Giorgis, M., Marini, E., Blua, F., Gallicchio, M., Spyrakis, F., MacDonald, J. A., et al. (2021) · Molecules · doi:10.3390/molecules26133975 · Cited by 19
Cited by
Newton, K., Strasser, A., Kayagaki, N., & Dixit, V. M. (2024) · Cell · doi:10.1016/j.cell.2023.11.044 · Cited by 990
The NLRP3 inflammasome: contributions to inflammation-related diseases
Chen, Y., Ye, X., Escames, G., Lei, W., Zhang, X., Li, M., Jing, T., Yao, Y., Qiu, Z., Wang, Z., et al. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00462-9 · Cited by 492
A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseases
Barnett, K. C., Li, S., Liang, K., & Ting, J. P.-Y. (2023) · Cell · doi:10.1016/j.cell.2023.04.025 · Cited by 458
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344
Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes
Pandeya, A., & Kanneganti, T.-D. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.10.001 · Cited by 303
Metadata
- Authors
- Coll, R. C., Schroder, K., & Pelegrín, P.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2022-08
- Volume
- 43
- Issue
- 8
- Pages
- 653-668
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W4225416470
- Cited by
- 755
- References
- 115
- FWCI
- 12.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.